Skip to main content

01.12.2014 | PRECLINICAL STUDIES | Ausgabe 6/2014

Investigational New Drugs 6/2014

A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer

Investigational New Drugs > Ausgabe 6/2014
Silvia Valtorta, Gabriella Nicolini, Farida Tripodi, Cristina Meregalli, Guido Cavaletti, Federica Avezza, Luca Crippa, Gloria Bertoli, Francesca Sanvito, Paola Fusi, Roberto Pagliarin, Fulvia Orsini, Rosa Maria Moresco, Paola Coccetti


The anticancer activity of a novel pure 1,4-Diaryl-2-azetidinone (1), endowed with a higher solubility than the well known Combretastatin A4, is tested in mice. We previously reported that Compound (1) showed specific antiproliferative activity against duodenal and colon cancer cells, inducing activation of AMP-activated protein kinase and apoptosis. Here we estimate that the maximum tolerated dose in a mouse model is 40 mg/kg; the drug is well tolerated both in single dose and in repeated administration schedules. The drug displays a significant antitumor activity and a tumor growth delay when administered at the MTD both in single and fractionated i.v. administration in a mouse xenograft model of colorectal cancer. Arrest of tumor growth and relapse after drug suspension are parallel to modification in glucose demand as shown by PET studies with [18 F] FDG. These data strongly support Compound (1) as a promising molecule for in vivo treatment of colorectal cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Über diesen Artikel

Weitere Artikel der Ausgabe 6/2014

Investigational New Drugs 6/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.